CAS:866460-33-5MF:C24H19FN2O3MW:402.4176632
Setipiprant(INN) (developmental code namesACT-129,968,KYTH-105) is adrugoriginally developed byActelionwhich acts as a selective, orally availableantagonistof theprostaglandin D2receptor 2(DP2).[1]It was initially researched as a treatment for allergies and inflammatory disorders, particularlyasthma, but despite being well tolerated inclinical trialsand showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,[2][3]it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
Formoredetailinformation,pleasefeelfreetocontactme.
For research use only!